Ck Life Sciences, also known as Ck Life Sciences International Holdings, is a prominent biotechnology company headquartered in Hong Kong. Founded in 2000, the company has established itself as a leader in the life sciences sector, focusing on innovative solutions in agricultural biotechnology and healthcare. With a strong presence in Asia and expanding operations globally, Ck Life Sciences is dedicated to developing unique products that enhance crop yields and improve human health. Their core offerings include advanced biopesticides and nutraceuticals, distinguished by their commitment to sustainability and efficacy. Recognised for its pioneering research and development, Ck Life Sciences has achieved significant milestones, positioning itself as a key player in the biotechnology industry. The company continues to drive advancements that contribute to a healthier and more sustainable future.
How does Ck Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ck Life Sciences's score of 39 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Ck Life Sciences reported total carbon emissions of approximately 31,245,000 kg CO2e for Scope 1 and about 16,250,000 kg CO2e for Scope 2, resulting in combined emissions of around 47,495,000 kg CO2e. This reflects a slight decrease from 2023, where emissions were approximately 32,037,000 kg CO2e for Scope 1 and 16,923,000 kg CO2e for Scope 2, totalling about 48,960,000 kg CO2e. Ck Life Sciences has set a long-term commitment to achieve net-zero emissions by 2050, as outlined in their NGFS Net Zero 2050 target, which commenced in 2019. This commitment encompasses all scopes of emissions, although specific reduction percentages have not been disclosed. The company does not currently report Scope 3 emissions, and their data is not cascaded from any parent organisation. Ck Life Sciences is actively working towards enhancing its sustainability practices and reducing its carbon footprint in alignment with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 9,297,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 14,229,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ck Life Sciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

